The biological in vitro effect and selectivity shown by a CoII complex of 2-(2-hydroxyphenylazo)-indole-3′-acetic acid on three distinctly different cancer cells. Issue 115 (12th December 2016)

• Record Type: Journal Article
• Authors: Ganguly, Durba; Jain, Chetan Kumar; Chandra Santra, Ramesh; Roychoudhury, Susanta; Majumder, Hemanta Kumar; Das, Saurabh
• Is Part Of: RSC advances. Volume 6:Issue 115(2016)
• Page Start: 114906
• Page End: 114915
• Publication Date: 2016-12-12
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/c6ra23163b
• Languages: English
• ISSNs: 2046-2069

Abstract

Abstract : Reductive cleavage of azo bond in a Co II complex of HPIA decreased significantly implying less toxicity. On human colon carcinoma HCT116, ALL MOLT-4 & MCF-7 breast cancer cells complex was more effective than HPIA but less toxic towards normal cells. Abstract : A major intention of this study was to use the modified toxicity of the azo moiety in [2-(2-hydroxyphenylazo)-1 H -indol-3-yl]-acetic acid (HPIA), achieved through complex formation with Co II on some cancer cell lines. This is important because the azo functional group has not been tried in cancer chemotherapy. Keeping in mind aspects of drug resistance of some of the common anticancer drugs, a serious problem and a major clinical challenge in cancer chemotherapy, it is essential that new molecules are identified with anticancer activity. Although cytotoxicity of azo compounds is established there are not many reports that utilize them in cancer treatment. Another important aspect is to prepare compounds having preferential activity on cancer cells over normal cells so that toxic side effects are a minimum. Enzyme assay on the reductive cleavage of the azo bond showed complex formation with Co II almost completely checked the generation of cytotoxic amines implying that the complex could be less cytotoxic which was actually observed in case of normal healthy cells. Even though the complex formed less cytotoxic amines and possessed an almost similar binding ability with DNA like that of HPIA surprisingly its activity on three cancer cell lines namely human colon carcinoma HCT116 cells, acute lymphoblastic leukemia MOLT-4 cells and MCF-7 breast cancer cells was much greater than HPIA. The difference in activity between HPIA and its Co II complex on cancer cells showed no correlation with DNA binding or amine formation like that observed for normal cells. The complex probably possesses multiple modes of action whereby it is able to inhibit one or more cellular processes or functioning of different enzymes involved in the cell cycle of cancer cells for which it was found more effective.